Nanologica AB (publ) has taken an order for the company's silica for preparative chromatography at a value of approximately MSEK 1.3. The order comes from Nanologica's reseller in China, Yunbo Technology (Beijing) Co. Ltd.
In July 2019, Nanologica signed an agreement with Chinese Yunbo Technology for the supply of silica for preparative chromatography worth approximately MUSD 14 (currently equivalent to approximately MSEK 150), between 2021 and 2026. The order that has now been placed is the first under this agreement.
"It is very gratifying to finally be able to take the first order within our agreement with Yunbo and it is a true milestone to now sell the first products from our large-scale production. This will be the first major delivery of our silica for preparative chromatography to the Chinese market. The customer, which is a manufacturer of peptides, intends to evaluate the silica in order to be able to include it in its production", CEO Andreas Bhagwani comments.
The order consists of several products where delivery of the first product type is expected to take place in the fourth quarter of this year.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company's share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit www.nanologica.com.
The information is information that Nanologica AB is obliged to make public pursuant to the EU Market Abuse Regulation). The information was submitted for publication, through the agency of the contact persons above, on August 31, 2022, at 15:10 (CET).
In July 2019, Nanologica signed an agreement with Chinese Yunbo Technology for the supply of silica for preparative chromatography worth approximately MUSD 14 (currently equivalent to approximately MSEK 150), between 2021 and 2026. The order that has now been placed is the first under this agreement.
"It is very gratifying to finally be able to take the first order within our agreement with Yunbo and it is a true milestone to now sell the first products from our large-scale production. This will be the first major delivery of our silica for preparative chromatography to the Chinese market. The customer, which is a manufacturer of peptides, intends to evaluate the silica in order to be able to include it in its production", CEO Andreas Bhagwani comments.
The order consists of several products where delivery of the first product type is expected to take place in the fourth quarter of this year.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company's share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit www.nanologica.com.
The information is information that Nanologica AB is obliged to make public pursuant to the EU Market Abuse Regulation). The information was submitted for publication, through the agency of the contact persons above, on August 31, 2022, at 15:10 (CET).
